vs
西蒙地产集团（ELS）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
西蒙地产集团的季度营收约是Guardant Health, Inc.的1.4倍（$397.6M vs $281.3M），Guardant Health, Inc.同比增速更快（39.4% vs 6.3%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 2.3%）
西蒙地产集团是美国头部房地产投资信托企业，投资范围涵盖购物中心、奥特莱斯及社区生活中心等商业地产业态，是美国规模最大的购物中心持有方，总部位于印第安纳州印第安纳波利斯，截至2024年12月末共持有232处物业权益。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
ELS vs GH — 直观对比
营收规模更大
ELS
是对方的1.4倍
$281.3M
营收增速更快
GH
高出33.0%
6.3%
两年增速更快
GH
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.6M | $281.3M |
| 净利润 | — | $-128.5M |
| 毛利率 | — | 64.6% |
| 营业利润率 | — | -43.0% |
| 净利率 | — | -45.7% |
| 营收同比 | 6.3% | 39.4% |
| 净利润同比 | — | -15.8% |
| 每股收益（稀释后） | $0.56 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELSGH
| Q1 26 | $397.6M | — | ||
| Q4 25 | $373.9M | $281.3M | ||
| Q3 25 | $393.3M | $265.2M | ||
| Q2 25 | $376.9M | $232.1M | ||
| Q1 25 | $387.3M | $203.5M | ||
| Q4 24 | $372.3M | $201.8M | ||
| Q3 24 | $387.3M | $191.5M | ||
| Q2 24 | $380.0M | $177.2M |
净利润ELSGH
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $-128.5M | ||
| Q3 25 | $100.4M | $-92.7M | ||
| Q2 25 | $83.5M | $-99.9M | ||
| Q1 25 | $114.4M | $-95.2M | ||
| Q4 24 | $100.6M | $-111.0M | ||
| Q3 24 | $86.9M | $-107.8M | ||
| Q2 24 | $82.1M | $-102.6M |
毛利率ELSGH
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% |
营业利润率ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 26.5% | -43.0% | ||
| Q3 25 | 25.1% | -37.3% | ||
| Q2 25 | 22.3% | -45.9% | ||
| Q1 25 | 28.3% | -54.6% | ||
| Q4 24 | 27.2% | -62.4% | ||
| Q3 24 | 21.4% | -61.3% | ||
| Q2 24 | 21.5% | -56.8% |
净利率ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 27.8% | -45.7% | ||
| Q3 25 | 25.5% | -35.0% | ||
| Q2 25 | 22.2% | -43.0% | ||
| Q1 25 | 29.5% | -46.8% | ||
| Q4 24 | 27.0% | -55.0% | ||
| Q3 24 | 22.4% | -56.3% | ||
| Q2 24 | 21.6% | -57.9% |
每股收益（稀释后）ELSGH
| Q1 26 | $0.56 | — | ||
| Q4 25 | $0.52 | $-1.01 | ||
| Q3 25 | $0.50 | $-0.74 | ||
| Q2 25 | $0.42 | $-0.80 | ||
| Q1 25 | $0.57 | $-0.77 | ||
| Q4 24 | $0.51 | $-0.90 | ||
| Q3 24 | $0.44 | $-0.88 | ||
| Q2 24 | $0.42 | $-0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $1.8B | $-99.3M |
| 总资产 | $5.7M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ELSGH
| Q1 26 | — | — | ||
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M |
总债务ELSGH
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $3.2B | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ELSGH
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $-99.3M | ||
| Q3 25 | $1.8B | $-354.5M | ||
| Q2 25 | $1.7B | $-305.5M | ||
| Q1 25 | $1.7B | $-250.8M | ||
| Q4 24 | $1.7B | $-139.6M | ||
| Q3 24 | $1.4B | $-60.1M | ||
| Q2 24 | $1.4B | $-1.6M |
总资产ELSGH
| Q1 26 | $5.7M | — | ||
| Q4 25 | $5.7B | $2.0B | ||
| Q3 25 | $5.7B | $1.3B | ||
| Q2 25 | $5.7B | $1.3B | ||
| Q1 25 | $5.6B | $1.3B | ||
| Q4 24 | $5.6B | $1.5B | ||
| Q3 24 | $5.6B | $1.5B | ||
| Q2 24 | $5.6B | $1.6B |
负债/权益比ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 1.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-54.2M |
| 自由现金流率自由现金流/营收 | — | -19.3% |
| 资本支出强度资本支出/营收 | — | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流ELSGH
| Q1 26 | — | — | ||
| Q4 25 | $571.1M | $-26.4M | ||
| Q3 25 | $147.0M | $-35.4M | ||
| Q2 25 | $131.3M | $-60.3M | ||
| Q1 25 | $193.4M | $-62.7M | ||
| Q4 24 | $596.7M | $-64.5M | ||
| Q3 24 | $149.5M | $-51.1M | ||
| Q2 24 | $143.1M | $-94.0M |
自由现金流ELSGH
| Q1 26 | — | — | ||
| Q4 25 | $334.1M | $-54.2M | ||
| Q3 25 | $75.7M | $-45.8M | ||
| Q2 25 | $71.8M | $-65.9M | ||
| Q1 25 | $148.2M | $-67.1M | ||
| Q4 24 | $355.4M | $-83.4M | ||
| Q3 24 | $91.1M | $-55.3M | ||
| Q2 24 | $80.6M | $-99.1M |
自由现金流率ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 89.4% | -19.3% | ||
| Q3 25 | 19.3% | -17.3% | ||
| Q2 25 | 19.1% | -28.4% | ||
| Q1 25 | 38.3% | -33.0% | ||
| Q4 24 | 95.5% | -41.3% | ||
| Q3 24 | 23.5% | -28.9% | ||
| Q2 24 | 21.2% | -55.9% |
资本支出强度ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 63.4% | 9.9% | ||
| Q3 25 | 18.1% | 3.9% | ||
| Q2 25 | 15.8% | 2.4% | ||
| Q1 25 | 11.7% | 2.2% | ||
| Q4 24 | 64.8% | 9.4% | ||
| Q3 24 | 15.1% | 2.2% | ||
| Q2 24 | 16.5% | 2.9% |
现金转化率ELSGH
| Q1 26 | — | — | ||
| Q4 25 | 5.50× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 5.93× | — | ||
| Q3 24 | 1.72× | — | ||
| Q2 24 | 1.74× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELS
| Rental income | $339.0M | 85% |
| Other | $37.2M | 9% |
| Annual membership subscriptions | $18.3M | 5% |
| Membership upgrade revenue | $3.1M | 1% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
